Large-cell lung carcinoma by the 2015 WHO classification：a clinicopathologic analysis of 93 cases
10.3760/cma.j.issn.0529-5807.2016.04.004
- VernacularTitle:基于2015年WHO新分类的93例大细胞肺癌临床病理分析
- Author:
Jingyuan ZHANG
1
;
Xinyu XU
;
Qin SHEN
;
Yanfen WANG
;
Xuan WANG
;
Xiaojun ZHOU
Author Information
1. 210002 南方医科大学南京临床学院/南京军区南京总医院病理科; 江苏省肿瘤医院病理科
- Keywords:
Lung neoplasms;
Carcinoma,large cell;
Immunohistochemistry;
Immunophenotyping;
Prognosis
- From:
Chinese Journal of Pathology
2016;45(4):231-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinicopathologic characteristics of large-cell lung carcinoma ( LCC) subtypes according to the 2015 WHO classification.Methods A total of 93 cases of LCC were identified among 1 634 cases of morphologically undifferentiated non-small cell lung carcinoma. Clinicopathologic and immunohistochemical characteristics were retrospectively reviewed.Results Among 93 cases of LCC, 50 cases were solid adenocarcinoma (53.8%), 21 cases were non-keratinzing squamous cell carcinoma ( 22.6%) , 3 cases were adenosquamous carcinoma ( 3.2%) , 8 cases were large cell carcinoma with unclear immunohistochemical features (8.6%) , and 11 cases were large cell carcinoma with null immunohistochemical features ( 11.8%) .No significant differences in clinical features were found among various immunophenotypes.The overall survival of 1, 3 and 5 years of all cases was 51.0%, 5.4%and 1.1%, respectively and the mean survival was ( 15.2 ±1.2 ) months.Notably the null type had the lowest survival rate of 18% in one year, significantly worse than those of solid adenocarcinoma and non-keratinzing squamous cell carcinoma. Conclusions The 2015 WHO classification based on immunohistochemical phenotype replaces the morphological approach in separating poorly differentiated non-small cell lung carcinoma from the former large cell lung carcinoma.The null immunohistochemical subtype may represent a distinct subtype of undifferentiated carcinoma with the worst prognosis.
